Manufacturing, Expression Systems

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

The company will build an additional commercial-scale, contract manufacturing facility for viral vectors and gene therapies near its existing site in Carlsbad, CA.

The technology enables the rapid production of large numbers of recombinant antibodies at 80-mL scale.

Single-use and modular systems will meet demand for rapid implementation at different scales.

The company presented data on its G2 glycosylation studies at the 15th European Conference on Fungal Genetics in Rome on Feb. 19, 2020.

GE Healthcare Life Sciences’ KUBio box is an integrated, flexible biomanufacturing environment for viral vector-based gene therapies.

In an effort to secure a continuous, sustainable supply of an important vaccine ingredient, Agenus is turning to a plant cell-based cell culture method for production.

Innovation in manufacturing technologies must occur to ensure the availability of gene and cell therapies.

The evolution of cell-culture technology is driving the need for improvements in modeling solutions.

As cost and time pressures within biopharma are on the rise, innovative expression systems may offer companies a good opportunity to streamline processes early on.

G-CON will provide a complete cleanroom infrastructure for GE Healthcare’s cell therapy and viral vector production platforms that will simplify early-stage manufacturing efforts.

The agreement gives Sanofi access to Biomunex’s proprietary bi- and multi-specific-antibody-generating platform.

A new facility in California will expand Orchard Therapeutic’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells.

A collaboration using Pall’s bioprocessing technology in G-CON’s PODs enables flexible continuous bioprocessing and viral vector facility solutions.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

The quality of the cell lines used to manufacture biopharmaceuticals are crucial for the production of high-quality, stable biopharmaceuticals.

Transcriptomics plays a role in influencing the production of recombinant therapeutics in microbial and mammalian hosts.

The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.

Anna Kireieva/Shutterstock.comSpeed to market is essential in the biopharmaceutical industry today.

The companies have entered into a strategic collaboration to establish a new cell therapy and regenerative medicine manufacturing platform, which includes a new manufacturing facility in Belgium.

The baculovirus-insect cell system can produce large quantities of complex protein in a short period of time.

The platform combines an expression system with equipment and process controls to enable rapid development and scale-up of robust titers.

Choosing the optimal protein expression vector depends on strain, promoter, and a number of other factors.

Under an NIH contract, Paragon Bioservices will design a manufacturing process for recombinant human rhE-selectin protein.

New human and plant-based expressions systems can enable faster product development and improve quality at potentially lower costs.

The author highlights novel strains and methods that have recently been shown to express multidisulfide bonded proteins.

Biosimilar manufacturers need better expression systems and analytical tools to compete.